Aimmune Therapeutics Inc (NASDAQ:AIMT) saw unusually large options trading on Thursday. Investors acquired 1,044 put options on the company. This represents an increase of approximately 876% compared to the typical daily volume of 107 put options.

Hedge funds have recently modified their holdings of the business. Carroll Financial Associates Inc. acquired a new stake in shares of Aimmune Therapeutics in the 4th quarter valued at $28,000. Bank of Montreal Can boosted its holdings in shares of Aimmune Therapeutics by 47.9% in the 4th quarter. Bank of Montreal Can now owns 1,516 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 491 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Aimmune Therapeutics by 84.6% in the 4th quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 796 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Aimmune Therapeutics by 37.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,609 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 708 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Aimmune Therapeutics in the 4th quarter valued at $96,000. 77.75% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have commented on AIMT shares. Cantor Fitzgerald started coverage on Aimmune Therapeutics in a research note on Sunday, December 9th. They set an “overweight” rating and a $23.75 price objective on the stock. Credit Suisse Group restated a “buy” rating and set a $40.00 price objective on shares of Aimmune Therapeutics in a research note on Tuesday, January 15th. BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. Roth Capital set a $80.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Monday, November 19th. Finally, Goldman Sachs Group assumed coverage on Aimmune Therapeutics in a report on Thursday, December 13th. They issued a “neutral” rating and a $32.00 target price on the stock. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $47.25.

Shares of AIMT stock opened at $23.34 on Friday. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.36 and a beta of -0.11. Aimmune Therapeutics has a fifty-two week low of $21.22 and a fifty-two week high of $36.12.

WARNING: “Aimmune Therapeutics Sees Unusually High Options Volume (AIMT)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2019/03/15/aimmune-therapeutics-sees-unusually-high-options-volume-aimt.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Story: How to interpret a stock’s beta number

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.